Fate Therapeutics, Inc. (FATE) Receives Buy Rating from HC Wainwright
Fate Therapeutics, Inc. (NASDAQ:FATE)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a research note issued to investors on Thursday, Marketbeat reports. They presently have a $7.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s price objective points to a potential upside of 70.32% from the company’s previous close.
Other equities analysts have also issued research reports about the stock. Zacks Investment Research upgraded shares of Fate Therapeutics from a “hold” rating to a “buy” rating and set a $4.75 price objective on the stock in a report on Friday, September 8th. ValuEngine upgraded shares of Fate Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, August 29th. Finally, Leerink Swann reiterated an “outperform” rating and issued a $7.00 price objective on shares of Fate Therapeutics in a report on Friday, September 8th. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $6.79.
Shares of Fate Therapeutics (NASDAQ:FATE) traded down 1.582% during mid-day trading on Thursday, hitting $4.045. The stock had a trading volume of 208,615 shares. The company’s 50 day moving average price is $3.97 and its 200 day moving average price is $3.68. Fate Therapeutics has a 12-month low of $1.80 and a 12-month high of $5.68. The stock’s market cap is $167.52 million.
COPYRIGHT VIOLATION NOTICE: This news story was originally published by American Banking News and is owned by of American Banking News. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/10/12/fate-therapeutics-inc-fate-coverage-initiated-by-analysts-at-hc-wainwright.html.
Several institutional investors have recently modified their holdings of the company. California State Teachers Retirement System acquired a new stake in shares of Fate Therapeutics in the 2nd quarter valued at about $219,000. State Street Corp acquired a new stake in shares of Fate Therapeutics in the 2nd quarter valued at about $1,437,000. OxFORD Asset Management LLP acquired a new stake in shares of Fate Therapeutics in the 2nd quarter valued at about $303,000. Vanguard Group Inc. raised its stake in shares of Fate Therapeutics by 9.4% in the 2nd quarter. Vanguard Group Inc. now owns 1,264,281 shares of the biopharmaceutical company’s stock valued at $4,096,000 after purchasing an additional 108,602 shares in the last quarter. Finally, Northern Trust Corp raised its stake in shares of Fate Therapeutics by 968.7% in the 2nd quarter. Northern Trust Corp now owns 368,208 shares of the biopharmaceutical company’s stock valued at $1,193,000 after purchasing an additional 333,753 shares in the last quarter. Institutional investors and hedge funds own 64.27% of the company’s stock.
About Fate Therapeutics
Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.
Receive News & Ratings for Fate Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.